Business
Publication of Positive MED2002 Clinical Data
Publication of Positive MED2002 Clinical Data.
About this update from Futura Medical Plc
[{"type":"text","content":"\n \nRNS Number : 9126A Futura Medical PLC 04 January 2018 \n\n\n\n\n\nFor immediate release \n\n\n4 January 2018\n\n\n\n\n \n \n \n \n \nFutura Medical plc\n(\"Futura\" or \"the Company\")\n \nPublication of Positive MED2002 Clinical Data\n \nFutura Medical plc (AIM: FUM), the innovative healthcare company focused on advanced transdermal technology, is pleased to announce the publication of positive data from its Phase II clinical trial of MED2002* in erectile dysfunction (\"ED\") in the peer-reviewed Journal of Sexual Medicine.\n \nThe article is available at this link: http://www.jsm.jsexmed.org/article/S1743-6095(17)31852-0/fulltext\n \nThe positive headline results of the Phase II trial were announced in September 2016 and showed that MED2002 has met its primary endpoint in showing a statistically significant improvement in erectile function in men with confirmed ED compared with placebo. The rapid onset of action of MED2002 means that it has the potential to be the world's fastest-acting treatment for ED.\n \nThe Journal of Sexual Medicine article includes further data from the Phase II study including details of positive secondary outcome measures. These show significant improvements with MED2002 in orgasmic function (p=0.012), sexual desire (p<0.0001), intercourse satisfaction (p=0.0055) and overall satisfaction (p=0.001) compared with placebo. These improvements are in standard measures used in the International Index of Erectile Function questionnaire (IIEF). The IIEF is considered the ''gold standard' measure for efficacy assessment in clinical trials of ED. The data includes the result that 70% of participants on average experienced onset of erection within 10 minutes.\n \nJames Barder, Futura's Chief Executive, said: \"The publication of the Phase II clinical data in the leading, peer-reviewed scientific journal in sexual medicine underlines the robustness of our previously reported study and demonstrates the level of scientific interest in MED2002. The article, in the Journal of Sexual Medicine, reinforces our belief that MED2002 has the potential to be the world's fastest-acting treatment for erectile dysfunction. MED2002 also has the potential to be a first-line treatment for ED patients who are unable to use existing oral treatment...